InsidersTradesSigma
Track the Larimar Therapeutics, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Larimar Therapeutics, Inc. has published 33 insider filings. Market capitalisation: €416.6m. The latest transaction was disclosed on 8 July 2026 (Acquisition). Among the most active insiders: Celano Michael. Every trade is accessible without an account.
33
Insider Decl.
n/a
Thresholds
€39m
19 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Larimar Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$14.40.
55Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 July 2026
Declarations33 total
50,000 shares@ US$3.33780.045% mcap6.0% of flowCommon StockSEC:0001193125-26-298523:0
Canonical exit: 4 Oct 2026 (T+90)
1,084,010 shares@ US$5.0012.7% of flowCommon StockSEC:0001193805-26-000205:0
Canonical exit: 28 May 2026 (T+90)
100,000 shares@ US$5.0017.3% of flowCommon StockSEC:0001193125-26-085515:0
Canonical exit: 28 May 2026 (T+90)
5,000 shares@ US$5.0050.8% of flowCommon StockSEC:0001193125-26-085514:0
Canonical exit: 28 May 2026 (T+90)
5,000 shares@ US$5.00100.0% of flowCommon StockSEC:0001193125-26-085510:0
Canonical exit: 28 May 2026 (T+90)
25,637 shares0Common StockSEC:0001193125-26-024833:0
25,637 shares0Common StockSEC:0001193125-26-024832:0
37,604 shares0Common StockSEC:0001193125-26-024824:0
100,100 shares0Common StockSEC:0001193125-26-024826:0
3,387,529 shares@ US$3.2030.1% of flowCommon StockSEC:0001193805-25-001155:0
Canonical exit: 29 Oct 2025 (T+90)
34,185 shares0Common StockSEC:0001062993-25-001077:0
23,306 shares0Common StockSEC:0001062993-25-001080:0
91,000 shares0Common StockSEC:0001062993-25-001078:0
23,306 shares0Common StockSEC:0001062993-25-001079:0
57,208 shares@ US$8.7420.2% of flowCommon StockSEC:0001062993-24-011568:0
Canonical exit: 16 May 2024 (T+90)
1,430,206 shares@ US$8.7448.9% of flowCommon StockSEC:0001193805-24-000245:0
Canonical exit: 16 May 2024 (T+90)
2,000 shares@ US$11.00100.0% of flowCommon StockSEC:0001062993-24-003312:0
Canonical exit: 14 May 2024 (T+90)
22,500 shares0Common StockSEC:0001062993-24-001086:0
22,500 shares0Common StockSEC:0001062993-24-001084:0
31,250 shares0Common StockSEC:0001062993-24-001085:0
66,125 shares0Common StockSEC:0001062993-24-001083:0
5,000 shares@ US$3.7323100.0% of flowCommon StockSEC:0001062993-23-022200:0
Canonical exit: 6 Mar 2024 (T+90)
2,750 shares@ US$3.73100.0% of flowCommon StockSEC:0001062993-23-011545:0
Canonical exit: 15 Aug 2023 (T+90)
5,000 shares@ US$3.726314.7% of flowCommon StockSEC:0001062993-23-011547:0
Canonical exit: 15 Aug 2023 (T+90)
5,000 shares@ US$3.70514.6% of flowCommon StockSEC:0001062993-23-011546:0
Canonical exit: 15 Aug 2023 (T+90)
25 of 33 declarations
关于 Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. 是一家在美国上市的临床阶段生物技术公司，在纳斯达克（NASDAQ）以股票代码 LRMR 交易。该公司总部位于宾夕法尼亚州巴拉辛维德（费城地区），并在特拉华州注册成立。它成立于 2005 年，当时名为 Zafgen, Inc.，后与 Chondrial Therapeutics 合并，更名为 Larimar Therapeutics。如今，Larimar 定位为一家高度专注的罕见病生物技术公司，其战略围绕着一条狭窄但可能创造价值的科学和监管途径。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm?utm_source=openai)） Larimar 的核心业务是开发 nomlabofusp，这是一种针对弗里德赖希共济失调（FA）的弗拉他星替代疗法。弗里德赖希共济失调是一种罕见的、进行性神经退行性疾病，治疗选择有限。该公司的科学论点是，恢复弗拉他星缺乏可能解决疾病的潜在生物学问题，而不仅仅是管理症状。Larimar 的历史平台也依赖于细胞穿透肽技术，这是其将蛋白质疗法递送至线粒体的方法的基础。这使得该公司成为一家典型的开发阶段生物技术公司，其价值主张取决于临床概念验证、监管执行、生产准备以及最终的商业化潜力。（[larimartx.com](https://larimartx.com/?utm_source=openai)） 从竞争角度来看，Larimar 在一个集中的罕见病领域运营，其差异化由作用机制、临床数据和监管定位驱动。该公司的主要资产一直在推进注册活动，2026 年 2 月，Larimar 宣布 FDA 授予 nomlabofusp 突破性疗法认定，用于治疗成人和儿童 FA 患者。Larimar 还表示，其与 FDA 的讨论支持使用皮肤弗拉他星作为计划于 2026 年 6 月提交的 BLA 申请中寻求加速批准的替代终点。这些更新很重要，因为它们表明了更清晰的监管路径，尽管投资案例仍高度依赖于执行和试验结果。（[investors.larimartx.com](https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-announces-fda-breakthrough-therapy?utm_source=openai)） 从地理上看，该公司的业务足迹主要在美国，公司和运营活动均在宾夕法尼亚州巴拉辛维德进行。Larimar 尚未成为一家商业化阶段的跨国公司；其存在主要是临床、监管和生产准备，而非广泛的全球销售。近期里程碑包括突破性疗法认定、正在进行的开放标签研究更新、支持皮肤作为弗拉他星测量替代组织的数据发布，以及 2025 年和 2026 年初为支持下一开发阶段而进行的融资活动。对于投资者而言，LRMR 最好被视为美国纳斯达克市场上一家高风险、高催化剂的生物技术公司，其上涨空间取决于 nomlabofusp 是否能成为 FA 的首创疾病修饰疗法。（[investors.larimartx.com](https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-announces-fda-breakthrough-therapy?utm_source=openai)）
